GlassScriptPhysician profile
Douglas J Raedy
NPI 1215111885
$4,967.06
in general payments reported to CMS, 2019-2025
25 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $495 · 2021: $1,404 · 2022: $425 · 2023: $455 · 2024: $642 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $1,992.81 | 2019-2021 | |
| Acclarent, INC | $635.01 | 2019-2023 | Acclarent Aera, Relieva Spinplus |
| Aerin Medical INC. | $420.54 | 2021-2025 | |
| Optinose US, INC. | $371.76 | 2019-2024 | |
| Stryker Corporation | $364.99 | 2019-2024 | Xpress Ent Dilation System, Medline Industries, INC. |
| Genzyme Corporation | $245.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $219.62 | 2021-2025 | Nucala |
| Integra Lifesciences Corporation | $124.01 | 2024-2025 | Integra, Inspira Air, Acclarent Aera |
| Fortovia Therapeutics, INC. | $61.42 | 2019-2020 | |
| Genentech USA, INC. | $55.85 | 2021-2024 | Xolair |
| Vertex Pharmaceuticals Incorporated | $48.26 | 2025 | |
| Pfizer INC. | $45.50 | 2020-2024 | |
| Kowa Pharmaceuticals America, INC. | $44.35 | 2022 | |
| Medtronic, INC. | $40.87 | 2024 | Pteye Parathyroid Detection System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.19 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $35.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.70 | 2024-2025 | Hyqvia, Eohilia |
| Phadia US INC. | $32.60 | 2023-2024 | Immunocap |
| Cochlear Americas | $28.27 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Novartis Pharmaceuticals Corporation | $26.51 | 2019 | |
| Ge Healthcare | $24.99 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.84 | 2025 | Neffy |
| Olympus America INC. | $21.67 | 2023 | |
| Hikma Pharmaceuticals USA | $16.50 | 2023 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $14.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Raedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.